Newsroom

Press Releases

April 9, 2024

Business Wire

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

November 30, 2023

Business Wire

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

October 19, 2023

Business Wire

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

April 4, 2023

Business Wire

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

November 8, 2022

Business Wire

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

September 28, 2022

Business Wire

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

Media

December 16, 2022

Richmond Biz Journals

Qnovia aims to bring smoking cessation medical device to market in 2025

December 16, 2022

MediaPost

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 16, 2022

Flipboard

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 13, 2022

PharmaShots

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

November 16, 2022

Pharmaphorum

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

November 2, 2022

Fortune

The role of board members during a market downturn

November 2, 2022

Yahoo! Finance

The role of board members during a market downturn

October 19, 2022

Coruzant Technologies

Brian Quigley

October 7, 2022

Drug Delivery Business

How Qnovia aims to use inhaled therapeutics for smoking cessation

December 4, 2023

Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study

November 30, 2023

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

October 19, 2023

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

April 4, 2023

Former FDA tobacco head: Smokers need a new tool to quit

April 4, 2023

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

March 31, 2023

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

February 24, 2023

Qnovia Raises $17 million for Nebulizer

January 8, 2023

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

December 27, 2022

Have a Project in Mind? Say Hi!

Newsroom

Press Releases

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

Media

Qnovia aims to bring smoking cessation medical device to market in 2025

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

The role of board members during a market downturn

The role of board members during a market downturn

Brian Quigley

How Qnovia aims to use inhaled therapeutics for smoking cessation

Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

Former FDA tobacco head: Smokers need a new tool to quit

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

Qnovia Raises $17 million for Nebulizer

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

Address:

Links